Flavia Castelino, MD / Sonye K. Danoff, MD, PhD - The Evolving Treatment Landscape of SSc-ILD: Strategies to Improve Recognition and Management
Manage episode 295692194 series 2942795
By PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to PeerView.com/RWP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, clinically heterogeneous, multisystem disease characterized by extensive fibrosis, autoimmunity, and vascular dysfunction. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Before 2019, immunosuppression was the mainstay of treatment; however, the recent FDA approval of the first antifibrotic agent specifically for the treatment of SSc-ILD now offers a new avenue of therapy for these patients. Evidence has shown that a multidisciplinary discussion—particularly the input of rheumatologists—often changes a diagnosis to one of the connective tissue disease–associated ILDs, including SSc-ILD, and consequently, the prognosis and treatment. This PeerView web broadcast underscores the importance of this collaboration and the best practices in the management of SSc-ILD. Our expert panel discusses the latest clinical data on antifibrotic therapy for SSc-ILD, as well as evidence-based treatment and recommendations for monitoring disease progression. Upon completion of this activity, participants should be better able to: Identify signs, symptoms, and patterns of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc), Recognize the importance of collaborating with other specialists in the diagnosis and management of SSc-ILD, Summarize the latest clinical data regarding efficacy and safety for the use of antifibrotic therapy for SSc-ILD, Apply best practices to the management of SSc-ILD, including evidence-based treatment and recommendations for monitoring disease progression.